Observed and predicted sorafenib concentrations from the final model were compared, as were changes over time. == Incidence of and time to hand-foot skin reaction == During the HATT trial, the study protocol was amended to include assessment of the impact of two different ointments on HFSR prevention. reduce the severity and incidence of all HFSR-associated parameters. Pharmacokinetic exposure was Turanose unaltered by ChildPugh progression. The final pharmacokinetic model predicted 13. 1 and 33. 8% reductions in sorafenib exposure over 6 and 12 months, respectively. == Conclusions == There was a trend of longer OS and TTP in Taiwanese patients with advanced HCC compared with patients with advanced HCC in the AsiaPacific trial. Sorafenib exposure did not correlate with liver function. Reduced pharmacokinetic exposure over time was unrelated to reduced or interrupted dosing. == Electronic supplementary material == The online version of this article (doi: 10. 1007/s12072-016-9774-x) contains supplementary material, which is available to authorized users. Keywords: Sorafenib, Advanced hepatocellular carcinoma, Metastatic hepatocellular carcinoma, Taiwanese patients, Overall survival, Turanose Time to progression == Turanose Introduction == Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common in the AsiaPacific region [1, 2]. Geographical differences in HCC incidence are largely due to variations in hepatitis B and C infection [3, 4]. In East Asia, including Taiwan, where hepatitis B virus (HBV) is endemic, the incidence rate of HCC is 2028 per 100, 000 people. Approximately 1020% of cases of HCC occur in patients with chronic HBV infection in the absence of cirrhosis. Two randomized, placebo-controlled, phase III trials, the Sorafenib HCC Assessment Randomized Protocol (SHARP) and the Sorafenib AsiaPacific (Sorafenib AP) trials, showed that the multikinase inhibitor sorafenib significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced HCC [5, 6]. Based on these results, sorafenib was approved as systemic treatment for patients with advanced HCC and remains the only globally approved systemic treatment for this disease. As a post-approval commitment in Taiwan, 151 patients were enrolled in this phase IV, single-arm study [Hepatocellular carcinomaAdvanced stagesorafenib Trial in Taiwanese patients (HATT)] to confirm the efficacy and safety of sorafenib. The requested number of patients was based on the number of patients from the mainland of China who were treated in the phase 3 AsiaPacific study (NCT00492752), which was 151 of the 226 randomized patients [5]. The main objective of the post-authorization study was to evaluate the safety and efficacy profile of sorafenib and Turanose to evaluate ChildPugh status progression in Taiwanese patients with advanced HCC cared for with sorafenib. The main examine did not include a primary endpoint. Another aim of this primary study was to assess the pharmacokinetics of sorafenib in sufferers with HCC. A substudy of hand-foot skin response (HFSR) reduction assessed HFSR incidence and grade/severity and time to HFSR in sufferers randomized to corticosteroid and noncorticosteroid Turanose ointment and in several nonrandomized, without treatment patients. == Methods == This potential, Tagln open-label, single-arm, post-authorization examine was carried out across eight sites in Taiwan in patients with advanced HCC. All sufferers meeting accessibility criteria received sorafenib 4 hundred mg (2 200-mg tablets) twice daily (BID) on the continuous plan. For the purpose of data recording, treatment period was divided into 21-day cycles. Treatment continued above radiologic development, provided the topic derived scientific benefit, while judged by the treating doctor. == Honest considerations == The trial protocol was approved by the institutional review boards of.